CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could less radiation be enough for HPV throat cancer?
Disease control OngoingThis study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC